UnknownNot Applicable

Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

United Kingdom400 participantsStarted 2021-12-01

Plain-language summary

A multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 90 days of age is sufficiently strong that a vaccine able to induce an immune response will lead to a meaningful decrease in the probability of iGBS disease.

Who can participate

Age range0 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Exclusion Criteria: For iGBS disease case recruitment, an infant is not eligible unless a parent/person with parental responsibility gives informed consent For iGBS disease control recruitment, a mother is not eligible unless she gives informed consent.

What they're measuring

Correlates objective

Timeframe: 36 months

Kinetics objective

Timeframe: 12 months

Trial details

NCT IDNCT04735419

SponsorSt George's, University of London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-30

Contact for this trial

Nadia Azzouzi

02082666488 nazzouzi@sgul.ac.uk

View on ClinicalTrials.gov More Streptococcus Agalactiae Infection trials